Anti-Coagulants - Mexico

Mexico

In Mexico, the revenue in the Anti-Coagulants market is expected to reach US$211.60m in 2024.
It is projected to show an annual growth rate of 7.27%, resulting in a market volume of US$300.60m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the market, with US$16,740.00m in 2024.
"Mexico's anti-coagulant market is witnessing a surge in demand due to the increasing prevalence of cardiovascular diseases among the country's aging population."

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Mexico has been steadily growing in recent years.

Customer preferences: Mexican consumers are becoming more health-conscious and are increasingly seeking preventative measures to avoid cardiovascular diseases. This has led to an increased demand for anti-coagulants, as they are commonly used to prevent blood clots that can lead to heart attacks or strokes. Additionally, the aging population in Mexico has also contributed to the growth of the anti-coagulants market, as elderly individuals are more likely to require blood thinners to manage their health.

Trends in the market: One trend in the Mexican anti-coagulants market is the increasing use of novel oral anticoagulants (NOACs) over traditional blood thinners like warfarin. NOACs are more convenient for patients as they do not require frequent blood tests and have fewer dietary restrictions. Additionally, the Mexican government has recently implemented policies to increase access to NOACs, which has further driven their adoption in the market.

Local special circumstances: Mexico has a large population of individuals with diabetes, which increases their risk of developing cardiovascular diseases and requiring anti-coagulants. Additionally, the country has a high prevalence of obesity, which is also a risk factor for heart disease. These local circumstances have contributed to the growth of the anti-coagulants market in Mexico.

Underlying macroeconomic factors: Mexico has a growing economy and an expanding middle class, which has led to increased spending on healthcare. Additionally, the country has a universal healthcare system that provides coverage for many prescription medications, including anti-coagulants. This has made these medications more accessible to the general population, further contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.